Science & Technology
Science and Technology
Science and Technology
Tue, July 20, 2010 
NASHUA, N.H.--([ BUSINESS WIRE ])--iCAD, Inc. (Nasdaq: ICAD), an industry-leading provider of advanced image analysis and workflow solutions for the early detection of cancer, today announced the launch of an MRI product suite for breast, prostate, and other organs. The product suite, which is a comprehensive quantitative image analysis solution, brings together the companya™s current products SpectraLook® and VividLook® with the new OmniLooka" and VersaVuea" Enterprise, to offer a comprehensive quantitative image analysis suite for cancer detection, staging, localization, treatment planning and serial monitoring.
"iCAD is 100% focused on developing and providing the most sophisticated image analysis solutions to help clinicians increase specificity and diagnostic confidence"
Advanced workflow and analysis tools simplify and streamline case review. The MRI Product suite features include:
- Integrated 3D/4D displays for rapid, efficient interpretation;
- Colorized displays on any underlying MR sequence;
- Fast and efficient creation of customized hanging protocols;
- Instant creation of 2D, 3D, MIP and MPR images from any image in the viewport on the fly;
- Advanced image manipulation icons in each viewport.
VersaVue Enterprise employs advanced thin client architecture to deliver real-time data access and eliminates the need to purchase redundant hardware. The software features on-demand viewing of studies anytime, anywhere to speed workflow as well as shared knowledge of study status from a single, shared database.
OmniLook, a complementary software module to iCADa™s existing breast MR (SpectraLook) and prostate MR (VividLook) solutions, applies advanced image analysis using a pharmacokinetic model for other organs of interest, such as liver, kidney and brain where dynamic contrast imaging may provide additional clinical insight. OmniLook gives clinicians the full flexibility to meet the clinical needs of a growing practice.
aiCAD is 100% focused on developing and providing the most sophisticated image analysis solutions to help clinicians increase specificity and diagnostic confidence,a said Rick Ortega, director of MRI programs at iCAD. aThe new advanced MRI product suite will improve workflow efficiencies to aid in expedient clinical decision making and treatment for patients, with an ultimate goal of delivering improved patient care.a
The new product suite, including VersaVue Enterprise, will be available in August 2010.
About iCAD, Inc.
iCAD, Inc. is an industry-leading provider of advanced image analysis and workflow solutions that enable healthcare professionals to better serve patients by identifying pathologies and pinpointing cancer earlier. iCAD offers a comprehensive range of high-performance, upgradeable Computer-Aided Detection (CAD) systems and workflow solutions for mammography (film-based, digital radiography and computed radiography), Magnetic Resonance Imaging (MRI) and Computed Tomography (CT). Since receiving FDA approval for the Companya™s first breast cancer detection product in 2002, more than 3,500 iCAD systems have been placed in healthcare practices worldwide. iCADa™s solutions aid in the early detection of the most prevalent cancers including breast and prostate, and in the future colon and lung cancer. For more information, call (877) iCADnow or visit [ www.icadmed.com ].
"Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995:
Certain statements contained in this News Release constitute aforward-looking statementsa within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve a number of known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Such factors include, but are not limited to, the risks of uncertainty of patent protection, the impact of supply and manufacturing constraints or difficulties, product market acceptance, possible technological obsolescence, increased competition, customer concentration and other risks detailed in the Companya™s filings with the Securities and Exchange Commission. The words abelievea, ademonstratea, aintenda, aexpecta, aestimatea, aanticipatea, alikelya, and similar expressions identify forward-looking statements. Readers are cautioned not to place undue reliance on those forward-looking statements, which speak only as of the date the statement was made. The Company is under no obligation to provide any updates to any information contained in this release.
